Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Active not recruiting 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 6Gynecologic 2Gastrointestinal 2Tumor-Agnostic 1Other solid neoplasm 1Head & Neck 1Genitourinary 1CNS 1Breast 1

Conditions

Ovarian Neoplasms 2Fallopian Tube Neoplasms 2

Interventions

Paclitaxel 143pembrolizumab 121Carboplatin 109Bevacizumab 93Cisplatin 69Specimen Handling 62olaparib 51Magnetic Resonance Spectroscopy 51Gemcitabine 41Nivolumab 36Biopsy 36liposomal doxorubicin 34Taxes 33Cyclophosphamide 31Blood Specimen Collection 31niraparib 28lenvatinib 26Letrozole 26Doxorubicin 26Topotecan 25Drug Therapy 25Immunoglobulin G 23Brachytherapy 22fludarabine 21atezolizumab 21Radiotherapy 21Disulfides 21durvalumab 20dostarlimab 19Surveys and Questionnaires 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
berzosertib × Gynecologic × 1 year × Clear all
NCT02595892 2026-04-13

Gemcitabine Hydrochloride Alone or With M6620 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
70 enrolled 23 charts
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02627443 2026-04-13

Carboplatin, Gemcitabine Hydrochloride, and Berzosertib in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

National Cancer Institute (NCI)

Phase 1 Active not recruiting
35 enrolled 13 charts
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡